Skip to main content

Table 1 Demographic characteristics of PWH and PrEP users

From: Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

Variable

HIV

N = 100

Prep

N = 100

p

Median age (IQR), year

50 (42–56)

39 (31–45)

 < 0.0001

Men, n

76

100

 < 0.0001

Sexual orientation, MSM, n

50

100

 < 0.0001

Country of birth, France, n

63

79

0.019

Family life, single n

59

81

0.001

Has children, no

42

4

 < 0.0001

Worker, no. (%)

71

90

0.001

Travels, no. (%)

  

 < 0.0001

 1–2/year

48

23

 

  > 2/year

34

75

 

 Never

17

2

 

Smoking status, current n

22

23

 > 0.99

Alcohol consumption, n

79

87

0.19

Illicit drugs consumption, n

28

56

 < 0.0001

Hypertension, n

25

8

0.002

Dyslipidemia, n

33

2

 < 0.0001

Diabetes mellitus, n

8

4

0.37

Depression, n

15

17

0.85

Antidepressant, n

9

5

0.41

Past experience with injectable, n

35

56

0.004

Partner aware of HIV or prep user status, n

76

91

0.007

Family aware of HIV or prep user status, n

48

24

0.0007

Friends aware of HIV or prep user status, n

47

74

0.0002

Hepatitis B virus coinfection, n

11

 

Hepatitis C virus coinfection, n

11

 

HIV exposure, years, mean, n

15

 

ART exposure > 10 years, n

58

 

Stade CDC, C, n

15

 

CD4 nadir (/mm3), mean

325

 

Current CD4 cell count (/mm3), mean

748

 

Viral load HIV-RNA < 50 copies/ml

100

 

Actual ART regimen OAD, n

95

 

Actual ART regimen STD, n

65

 

2NRTI + NNRTI, n

30

 

2 NRTI + IP/r, n

9

  

2 NRTI + II, n

52

 

Other combination, n

9